US12573485B2 - Selection of antibodies / antibody fragments - Google Patents
Selection of antibodies / antibody fragmentsInfo
- Publication number
- US12573485B2 US12573485B2 US16/929,585 US202016929585A US12573485B2 US 12573485 B2 US12573485 B2 US 12573485B2 US 202016929585 A US202016929585 A US 202016929585A US 12573485 B2 US12573485 B2 US 12573485B2
- Authority
- US
- United States
- Prior art keywords
- pool
- genes
- gene
- count
- observed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Molecular Biology (AREA)
- Primary Health Care (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
-
- receiving features relating to VL genes and VH genes, the VL genes and VH genes encoding the variable domains of light and heavy chains of antibodies and/or antibody fragments, the antibodies and/or antibody fragments originating from a selection method, the selection method comprising multiple successive selection cycles, the result of each selection cycle being a pool containing antibodies and/or antibody fragments,
- forming feature vectors for pairs of VL genes and VH genes in the pools, the VL gene and the VH gene of each pair encoding variable domains belonging to the same antibody and/or antibody fragment, each feature vector for a pool comprising at least the following features:
- count of the VL gene in the particular pool,
- count of the VH gene in the particular pool,
- count of the VL gene in the preceding pool,
- count of the VH gene in the preceding pool,
- the absolute difference between the count of the VH gene in the particular pool and the count of the VL gene in the particular pool,
- the absolute difference between the count of the VH gene in the preceding pool and the count of the VL gene in the preceding pool,
- identifying enrichment patterns in the feature vectors of the pools, enrichment patterns showing the strength of enrichment of the antibody and/or antibody fragment with the particular VL gene and VH gene in the selection method,
- ascertaining score values for pairs of VL genes and VH genes on the basis of the enrichment patterns, the score values correlating with the respective strength of enrichment,
- optionally: ascertaining a ranking list for pairs of VL genes and VH genes on the basis of the score values,
- outputting the score values and/or the ranking list to a user.
-
- an input unit,
- a feature vector generation unit,
- an enrichment analysis unit,
- a score value calculation unit,
- a ranking unit and
- an output unit,
- the input unit being configured to acquire features relating to VL genes and VH genes encoding variable domains of light and heavy chains of antibodies and/or antibody fragments, the antibodies and/or antibody fragments originating from a selection method, the selection method comprising multiple successive selection cycles, the result of each selection cycle being a pool containing antibodies and/or antibody fragments,
- the feature vector generation unit being configured to generate feature vectors for pairs of VL and VH genes in the pools on the basis of the acquired features, the VL gene and the VH gene of each pair encoding variable domains belonging to the same antibody and/or antibody fragment, each feature vector for a pool comprising at least the following features:
- count of the VL gene in the particular pool,
- count of the VH gene in the particular pool,
- count of the VL gene in the preceding pool,
- count of the VH gene in the preceding pool,
- the absolute difference between the count of the VH gene in the particular pool and the count of the VL gene in the particular pool,
- the absolute difference between the count of the VH gene in the preceding pool and the count of the VL gene in the preceding pool,
- the enrichment analysis unit being configured to identify enrichment patterns in the feature vectors of the pools, enrichment patterns showing the strength of enrichment of the antibody and/or antibody fragment with the particular VL gene and VH gene in the selection method,
- the score value calculation unit being configured to calculate score values for pairs of VL genes and VH genes on the basis of the enrichment patterns, the score values correlating with the respective strength of enrichment,
- the ranking unit being preferably configured to calculate a ranking list for pairs of VL genes and VH genes on the basis of the score values,
- the output unit being configured to output the score values and/or the ranking list to a user.
-
- receiving features relating to VL genes and VH genes, the VL genes and VH genes encoding the variable domains of light and heavy chains of antibodies and/or antibody fragments, the antibodies and/or antibody fragments originating from a selection method, the selection method comprising multiple successive selection cycles, the result of each selection cycle being a pool containing antibodies and/or antibody fragments,
- forming feature vectors for pairs of VL genes and VH genes in the pools, the VL gene and the VH gene of each pair encoding variable domains belonging to the same antibody and/or antibody fragment, each feature vector for a pool comprising at least the following features:
- count of the VL gene in the particular pool,
- count of the VH gene in the particular pool,
- count of the VL gene in the preceding pool,
- count of the VH gene in the preceding pool,
- the absolute difference between the count of the VH gene in the particular pool and the count of the VL gene in the particular pool,
- the absolute difference between the count of the VH gene in the preceding pool and the count of the VL gene in the preceding pool,
- identifying enrichment patterns in the feature vectors of the pools, enrichment patterns showing the strength of enrichment of the antibody and/or antibody fragment with the particular VL gene and VH gene in the selection method,
- ascertaining score values for pairs of VL genes and VH genes on the basis of the enrichment patterns, the score values correlating with the respective strength of enrichment,
- optionally: ascertaining a ranking list for pairs of VL genes and VH genes on the basis of the score values,
- outputting the score values and/or the ranking list to a user.
-
- count of the VL gene in the particular pool (preferably in the form of the absolute number VL of VL genes in the pool or in normalized form),
- count of the VH gene in the particular pool (preferably in the form of the absolute number VH of VH genes in the pool or in normalized form),
- count of the VL gene in the preceding pool (preferably in the form of the absolute number prevVL of the VL gene in the preceding pool or in normalized form)
- count of the VH gene in the preceding pool (preferably in the form of the absolute number prevVH of the VH gene in the preceding pool or in normalized form)
- the absolute difference (diff) between the count of the VH gene in the particular pool and the count of the VL gene in the particular pool (diff=|VH-VL|)
- the absolute difference (prevDiff) between the count of the VH gene in the preceding pool and the count of the VL gene in the preceding pool (prevDiff=|prevVH-prevVL|).
rpmVH=(VH/sumVH)*1000000
rpmVL=(VL/sumVL)*1000000
-
- where rpmVH is the normalized count of the VH genes in the observed pool,
- where rpmVL is the normalized count of the VL genes in the observed pool,
- where sumVH is the sum of the absolute counts VH of all VH genes in the observed pool,
- where sumVL is the sum of the absolute counts VL of all VL genes in the observed pool.
-
- the absolute number (count) of different VH genes in the observed pool: numVH
- the absolute number (count) of different VL genes in the observed pool: numVL
- the absolute number (count) of that VH gene which is present in the observed pool with the greatest count: maxVH
- the absolute number (count) of that VL gene which is present in the observed pool with the greatest count: maxVL
- the relative count of the VH gene in the observed pool (based on the number of the VH gene which occurs in the observed pool with the greatest count): relVH=VH/maxVH
- the relative count of the VL gene in the observed pool (based on the number of the VL gene which occurs in the observed pool with the greatest count): relVL=VL/maxVL
- the relative difference (relative distance) between the count of the VH gene in the observed pool and the count of the VL gene in the observed pool (in relation to the count of that gene in the observed pool which occurs with a greater count): reldiff=|VH-VL|/max(VH, VL), where max(VH, VL)=H for VH>VL and max(VH, VL)=VL for VL≥VH
- the number of selection cycles (levels) which were passed through before the observed selection cycle: prevnum
- normalized count of the VH genes in the observed pool: rpmVH=(VH/sumVH)*1000000, where sumVH is the sum of the counts VH of all VH genes in the observed pool
- normalized count of the VL genes in the observed pool: rpmVL=(VL/sumVL)*1000000, where sumVL is the sum of the counts VL of all VL genes in the observed pool
- normalized count of the VH genes in the preceding pool: prevRpmVH=(prevVH/prevSumVH)*1000000, where prevSumVH is the sum of the counts VH of all VH genes in the preceding pool
- normalized count of the VL genes in the preceding pool: prevRpmVL=(prevVL/prevSumVL)*1000000, where prevSumVL is the sum of the counts VL of all VL genes in the preceding pool
- the relative change in the number of VH genes from the first selection cycle to the second selection cycle: prevRelDiffVH=(|VH-prevVH|)/max(VH, prevVH), where max(VH, prevVH)=VH for VH>prevVH and max(VH, prevVH)=prevVH for prevVH≥VH
- the relative change in the number of VL genes from the first selection cycle to the second selection cycle: prevRelDiffVL=(|VL-prevVL|)/max(VL, prevVL), where max(VL, prevVL)=VL for VL>prevVL and max(VL, prevVL)=prevVL for prevVL≥VL
- the logarithm to the base 2 of the ratio of the normalized count of the VH genes in the observed pool to the normalized count of the VH genes in the preceding pool: logRpmVH=log 2(rpmVH/prevRpmsVH)
- the logarithm to the base 2 of the ratio of the normalized count of the VL genes in the observed pool to the normalized count of the VL genes in the preceding pool: logRpmVL=log 2(rpmVL/prevRpmsVL)
-
- to prompt the input unit (110) to receive features M relating to VL genes and VH genes, the VL genes and VH genes encoding the variable domains of light and heavy chains of antibodies and/or antibody fragments, the antibodies and/or antibody fragments originating from a selection method, the selection method comprising multiple successive selection cycles, the result of each selection cycle being a pool containing antibodies and/or antibody fragments,
- to generate feature vectors for pairs of VL genes and VH genes in the pools, the VL gene and the VH gene of each pair encoding variable domains belonging to the same antibody and/or antibody fragment,
- to generate factors for the pairs of VL genes and VH genes in a pool on the basis of the feature vectors, the factors describing the properties of the pairs in a pool with a lower number of variables than the feature vectors,
- to calculate score values for pairs of VL genes and VH genes on the basis of the factors,
- to generate a ranking list R for pairs of VL genes and VH genes on the basis of the score values,
- to prompt the output unit (160) to output the ranking list R to a user P.
-
- (210) receiving features M relating to VL genes and VH genes, the VL genes and VH genes encoding the variable domains of light and heavy chains of antibodies and/or antibody fragments, the antibodies and/or antibody fragments originating from a selection method, the selection method comprising multiple successive selection cycles, the result of each selection cycle being a pool containing antibodies and/or antibody fragments, (220) forming feature vectors MV for pairs of VL genes and VH genes in the pools on the basis of the features M, the VL gene and the VH gene of each pair encoding variable domains belonging to the same antibody and/or antibody fragment, each feature vector for a pool comprising at least the following features:
- count of the VL gene in the particular pool,
- count of the VH gene in the particular pool,
- count of the VL gene in the preceding pool,
- count of the VH gene in the preceding pool,
- the absolute difference between the count of the VH gene in the particular pool and the count of the VL gene in the particular pool,
- the absolute difference between the count of the VH gene in the preceding pool and the count of the VL gene in the preceding pool,
- (230) ascertaining factors F for the pairs of VL genes and VH genes in a pool on the basis of the feature vectors MV, the factors F describing the properties of the pairs in a pool with a lower number of variables than the feature vectors,
- (240) ascertaining score values S for pairs of VL genes and VH genes on the basis of the factors F,
- (250) ascertaining a ranking list R for pairs of VL genes and VH genes on the basis of the score values S,
- (260) outputting the ranking list R to a user P.
- (210) receiving features M relating to VL genes and VH genes, the VL genes and VH genes encoding the variable domains of light and heavy chains of antibodies and/or antibody fragments, the antibodies and/or antibody fragments originating from a selection method, the selection method comprising multiple successive selection cycles, the result of each selection cycle being a pool containing antibodies and/or antibody fragments, (220) forming feature vectors MV for pairs of VL genes and VH genes in the pools on the basis of the features M, the VL gene and the VH gene of each pair encoding variable domains belonging to the same antibody and/or antibody fragment, each feature vector for a pool comprising at least the following features:
-
- information about the observed VH gene (e.g. an unambiguous identifier)
- information about the observed VL gene (e.g. an unambiguous identifier)
- the absolute number VH (count) of the observed VH gene in the pool from the second selection cycle
- the absolute number VL (count) of the observed VL gene in the pool from the second selection cycle
- the absolute number numVH (count) of different VH genes in the pool from the second selection cycle
- the absolute number numVL (count) of different VL genes in the pool from the second selection cycle
- the absolute number maxVH (count) of that VH gene which is present in the pool from the second selection cycle with the greatest count
- the absolute number maxVL (count) of that VL gene which is present in the pool from the second selection cycle with the greatest count
- the relative count relVH of the VH gene in the pool from the second selection cycle (based on the number of the VH gene which occurs in the pool from the second selection cycle with the greatest count): relVH=VH/maxVH
- the relative count relVL of the VL gene in the pool from the second selection cycle (based on the number of the VL gene which occurs in the pool from the second selection cycle with the greatest count): relVL=VL/maxVL
- the difference diff (distance) between the count of the observed VH gene in the pool from the second selection cycle and the count of the observed VL gene in the pool from the second selection cycle (as amount): diff=|VH-VL|
- the relative difference relDiff (relative distance) between the count of the VH gene in the pool from the second selection cycle and the count of the VL gene in the pool from the second selection cycle (in relation to the count of that gene in the pool from the second selection cycle which occurs with a greater count): relDiff=|VH-VL|/max(VH, VL), where max(VH, VL)=VH for VH>VL and max(VH, VL)=VL for VL≥VH
- the number prevnum of selection cycles (levels) which were passed through before the second selection cycle
- the absolute number prevVH of the VH gene in the pool from the first selection cycle
- the absolute number prevVL of the VL gene in the pool from the first selection cycle
- the difference prevDiff (distance) between the count of the VH gene from the pool of the first selection cycle and the count of the VL gene from the pool of the first selection cycle (as amount): prevDiff=|prevVH-prevVL|
- the relative change in the number of VH genes from the first selection cycle to the second selection cycle: prevRelDiffVH=(|VH-prevVH|)/max(VH, prevVH), where max(VH, prevVH)=VH for VH>prevVH and max(VH, prevVH)=prevVH for prevVH≥VH
- the relative change in the number of VL genes from the first selection cycle to the second selection cycle: prevRelDiffVL=(|VL-prevVL|)/max(VL, prevVL), where max(VL, prevVL)=VL for VL>prevVL and max(VL, prevVL)=prevVL for prevVL≥VL
Claims (11)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19/538,804 US20260179749A1 (en) | 2019-07-18 | 2026-02-12 | Selection of antibodies / antibody fragments |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19187005.4 | 2019-07-18 | ||
| EP19187005 | 2019-07-18 | ||
| EP19187005 | 2019-07-18 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US19/538,804 Continuation US20260179749A1 (en) | 2019-07-18 | 2026-02-12 | Selection of antibodies / antibody fragments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20210020286A1 US20210020286A1 (en) | 2021-01-21 |
| US12573485B2 true US12573485B2 (en) | 2026-03-10 |
Family
ID=67437990
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16/929,585 Active 2042-01-11 US12573485B2 (en) | 2019-07-18 | 2020-07-15 | Selection of antibodies / antibody fragments |
| US19/538,804 Pending US20260179749A1 (en) | 2019-07-18 | 2026-02-12 | Selection of antibodies / antibody fragments |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US19/538,804 Pending US20260179749A1 (en) | 2019-07-18 | 2026-02-12 | Selection of antibodies / antibody fragments |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US12573485B2 (en) |
| EP (1) | EP3767628B1 (en) |
| CN (1) | CN112242181B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013078455A2 (en) * | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Proteomic identification of antibodies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001062907A1 (en) * | 2000-02-22 | 2001-08-30 | Medical & Biological Laboratories Co., Ltd. | Antibody library |
| DE60142840D1 (en) | 2000-09-08 | 2010-09-30 | Univ Texas | BY PHAGENDISPLAY IDENTIFIED TARGET PEPTIDES OF HUMANS AND MOUSE |
| CA2456121A1 (en) * | 2001-08-03 | 2003-02-20 | Medical Research Council | Intracellular antibodies |
| EA015992B1 (en) * | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Stabilized antibody and multivalent antibinding molecule based thereon, methods for making thereof and use such stabilized antibody |
| US8131480B2 (en) * | 2006-10-02 | 2012-03-06 | Sea Lane Biotechnologies Llc | Construction of diverse synthetic peptide and polypeptide libraries |
| NZ581468A (en) * | 2007-06-25 | 2012-09-28 | Esbatech Alcon Biomed Res Unit | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| CA2799746C (en) * | 2010-05-17 | 2020-11-24 | Sai Reddy | Rapid isolation of monoclonal antibodies from animals |
| US12404552B2 (en) * | 2015-07-17 | 2025-09-02 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods of selecting antibodies and antibody fragments |
| EP3561703B1 (en) | 2018-04-25 | 2021-01-20 | Bayer AG | Identification of the mating of variable domains from light and heavy chains of antibodies |
-
2020
- 2020-07-10 EP EP20185117.7A patent/EP3767628B1/en active Active
- 2020-07-15 US US16/929,585 patent/US12573485B2/en active Active
- 2020-07-17 CN CN202010695677.7A patent/CN112242181B/en active Active
-
2026
- 2026-02-12 US US19/538,804 patent/US20260179749A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013078455A2 (en) * | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Proteomic identification of antibodies |
| US20130178370A1 (en) | 2011-11-23 | 2013-07-11 | The Board Of Regents Of The University Of Texas System | Proteomic identification of antibodies |
Non-Patent Citations (18)
| Title |
|---|
| Chaudhary, N. et al. (Mar. 14, 2018). "Analyzing Immunoglobulin Repertoires," Frontiers in Immunology 9(462): 1-18. |
| DeKosky, B. et al. (Jan. 2015). "In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire," Nature Medicine, 21(1), 86-93. |
| DeKosky, B., Kojima, T., Rodin, A. et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nat Med 21, 86-91 (2015) (Year: 2015). * |
| Glenn Deng et al. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Research 2008, 10:R69 (Year: 2008). * |
| He, L. et al. (Aug. 24, 2017). "Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer," Frontiers in Immunology 8(1025): 1-21. |
| Jonathan A. Schumacher et al. Evaluation of Enrichment Techniques for Mass Spectrometry. Journal of Molecular Diagnostics, vol. 9, No. 2, Apr. 2007 (Year: 2007). * |
| Kaplinsky, J. et al. (Jun. 9, 2014). "Antibody repertoire deep sequencing reveals antigen-independent selection in maturing B cells," PNAS DOI: 10.1073/pnas.1403278111, E2622-E2629. |
| Upadhyay, A. et al. (Mar. 20, 2018). "BALDR: a computational pipeline for paired heavy and light chain immunoglobulin reconstruction in single-cell RNA-seq data," Genome Medicine, 10:20, 1-18. |
| Upadhyay, A.A., Kauffman, R.C., Wolabaugh, A.N. et al. BALDR: a computational pipeline for paired heavy and light chain immunoglobulin reconstruction in single-cell RNA-seq data. Genome Med 10, 20 (2018). (Year: 2018). * |
| Chaudhary, N. et al. (Mar. 14, 2018). "Analyzing Immunoglobulin Repertoires," Frontiers in Immunology 9(462): 1-18. |
| DeKosky, B. et al. (Jan. 2015). "In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire," Nature Medicine, 21(1), 86-93. |
| DeKosky, B., Kojima, T., Rodin, A. et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nat Med 21, 86-91 (2015) (Year: 2015). * |
| Glenn Deng et al. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Research 2008, 10:R69 (Year: 2008). * |
| He, L. et al. (Aug. 24, 2017). "Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer," Frontiers in Immunology 8(1025): 1-21. |
| Jonathan A. Schumacher et al. Evaluation of Enrichment Techniques for Mass Spectrometry. Journal of Molecular Diagnostics, vol. 9, No. 2, Apr. 2007 (Year: 2007). * |
| Kaplinsky, J. et al. (Jun. 9, 2014). "Antibody repertoire deep sequencing reveals antigen-independent selection in maturing B cells," PNAS DOI: 10.1073/pnas.1403278111, E2622-E2629. |
| Upadhyay, A. et al. (Mar. 20, 2018). "BALDR: a computational pipeline for paired heavy and light chain immunoglobulin reconstruction in single-cell RNA-seq data," Genome Medicine, 10:20, 1-18. |
| Upadhyay, A.A., Kauffman, R.C., Wolabaugh, A.N. et al. BALDR: a computational pipeline for paired heavy and light chain immunoglobulin reconstruction in single-cell RNA-seq data. Genome Med 10, 20 (2018). (Year: 2018). * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20260179749A1 (en) | 2026-06-25 |
| US20210020286A1 (en) | 2021-01-21 |
| EP3767628B1 (en) | 2024-03-27 |
| CN112242181B (en) | 2025-03-04 |
| CN112242181A (en) | 2021-01-19 |
| EP3767628A1 (en) | 2021-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230207068A1 (en) | Methods of Profiling Mass Spectral Data Using Neural Networks | |
| Liberis et al. | Parapred: antibody paratope prediction using convolutional and recurrent neural networks | |
| Chen et al. | Protein-protein interaction prediction using a hybrid feature representation and a stacked generalization scheme | |
| Ayoglu et al. | Antigen arrays for profiling autoantibody repertoires | |
| Kukreja et al. | Comparative study of classification algorithms for immunosignaturing data | |
| KR20210076122A (en) | Systems and Methods for Active Transfer Learning Including Deep Characterization | |
| JP2023526188A (en) | Biopharmaceutical engineering via aptamer mimetic discovery | |
| CN112041487B (en) | Identification of pairing of antibody light and heavy chain variable domains | |
| Tran et al. | Deep omics | |
| Li et al. | Antibody representation learning for drug discovery | |
| Chhibbar et al. | Machine learning approaches enable the discovery of therapeutics across domains | |
| CN115171811A (en) | Medicine virtual screening method based on capsule dynamic attention mechanism | |
| US20210020286A1 (en) | Selection of antibodies / antibody fragments | |
| US12424300B1 (en) | Conditional multicapitate neural networks for AI-based protein and drug design | |
| Chen et al. | Domain-based predictive models for protein-protein interaction prediction | |
| Chinery et al. | Simple computational methods can outperform deep learning in designing diverse, binder-enriched antibody libraries | |
| Carter et al. | Machine learning model interpretations explain T cell receptor binding | |
| Kathuria et al. | Determining protein conformation using vibrational frequencies: an ensemble approach | |
| Yang et al. | CETSA feature based clustering for protein outlier discovery by protein-to-protein interaction prediction | |
| Nafi et al. | StackGlyEmbed: prediction of N-linked glycosylation sites using protein language models | |
| Brasier et al. | Analysis and predictive modeling of asthma phenotypes | |
| Abeer et al. | Structure-based TCR-pMHC binding prediction and generalization to unseen peptides | |
| Arora et al. | Challenges for machine learning in RNA-protein interaction prediction | |
| Amiaud-Plachy et al. | Bayes-PD: Exploring a Sequence to Binding Bayesian Neural Network model trained on Phage Display data | |
| US12450409B1 (en) | CAM-guided transformers for AI-based protein and drug design |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| AS | Assignment |
Owner name: BAYER AKTIENGESELLSCHAFT, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BENDER, CHRISTIAN;VOELKER, JOHANNA;SIGNING DATES FROM 20200925 TO 20200930;REEL/FRAME:054017/0594 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: ALLOWED -- NOTICE OF ALLOWANCE NOT YET MAILED Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |